Philippe Joubert
Overview
Explore the profile of Philippe Joubert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
131
Citations
3321
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Boumtje V, Manikpurage H, Li Z, Gaudreault N, Armero V, Boudreau D, et al.
EBioMedicine
. 2024 Jul;
106:105234.
PMID: 38970920
Background: The most near-term clinical application of genome-wide association studies in lung cancer is a polygenic risk score (PRS). Methods: A case-control dataset was generated consisting of 4002 lung cancer...
12.
Renaut S, Armero V, Boudreau D, Gaudreault N, Desmeules P, Theriault S, et al.
PLoS Genet
. 2024 May;
20(5):e1011301.
PMID: 38814983
Whether single-cell RNA-sequencing (scRNA-seq) captures the same biological information as single-nucleus RNA-sequencing (snRNA-seq) remains uncertain and likely to be context-dependent. Herein, a head-to-head comparison was performed in matched normal-adenocarcinoma human...
13.
Bosse Y, Dasgupta A, Abadier M, Guthrie V, Song F, Armero V, et al.
Cancer Lett
. 2024 May;
594:216984.
PMID: 38797230
Background: Circulating tumor DNA (ctDNA) positivity at diagnosis, which is associated with worse outcomes in multiple solid tumors including stage I-III non-small cell lung cancer (NSCLC), may have utility to...
14.
Shrine N, Guyatt A, Erzurumluoglu A, Jackson V, Hobbs B, Melbourne C, et al.
Nat Genet
. 2024 Apr;
56(5):1032-1033.
PMID: 38641645
No abstract available.
15.
Travis W, Eisele M, Nishimura K, Aly R, Bertoglio P, Chou T, et al.
J Thorac Oncol
. 2024 Mar;
19(7):1028-1051.
PMID: 38508515
Introduction: Spread through air spaces (STAS) consists of lung cancer tumor cells that are identified beyond the edge of the main tumor in the surrounding alveolar parenchyma. It has been...
16.
Vahidian F, Lamaze F, Bouffard C, Coulombe F, Gagne A, Blais F, et al.
Cancers (Basel)
. 2024 Feb;
16(4).
PMID: 38398098
Immune checkpoint inhibitors (ICIs) have revolutionized non-small cell lung cancers (NSCLCs) treatment, but only 20-30% of patients benefit from these treatments. Currently, PD-L1 expression in tumor cells is the only...
17.
Dia A, Ebrahimpour L, Yolchuyeva S, Tonneau M, Lamaze F, Orain M, et al.
Cancers (Basel)
. 2024 Jan;
16(2).
PMID: 38254838
Background: Recent advances in cancer biomarker development have led to a surge of distinct data modalities, such as medical imaging and histopathology. To develop predictive immunotherapy biomarkers, these modalities are...
18.
Yolchuyeva S, Ebrahimpour L, Tonneau M, Lamaze F, Orain M, Coulombe F, et al.
J Transl Med
. 2024 Jan;
22(1):42.
PMID: 38200511
Background: Immune checkpoint inhibitors (ICIs) have emerged as one of the most promising first-line therapeutics in the management of non-small cell lung cancer (NSCLC). However, only a subset of these...
19.
Tankel J, Spicer J, Chu Q, Fiset P, Kidane B, Leighl N, et al.
Curr Oncol
. 2023 Dec;
30(12):10363-10384.
PMID: 38132389
The treatment paradigm for patients with stage II/III non-small-cell lung cancer (NSCLC) is rapidly evolving. We performed a modified Delphi process culminating at the Early-stage Lung cancer International eXpert Retreat...
20.
Yolchuyeva S, Giacomazzi E, Tonneau M, Lamaze F, Orain M, Coulombe F, et al.
JTO Clin Res Rep
. 2023 Dec;
4(12):100602.
PMID: 38124790
Background: Although the immune checkpoint inhibitors, nivolumab and pembrolizumab, were found to be promising in patients with advanced NSCLC, some of them either do not respond or have recurrence after...